secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039867
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma Q2 net loss $17.9M; positive Phase 2a NASH data for TERN-501
-------------------------------------------------------------------------

- Net loss of $17.9M ($0.25 per share) vs $13.9M a year ago; R&D spend $14.2M.
- Cash $285.6M, expected to fund operations into 2026.
- Positive Phase 2a DUET trial: TERN-501 met all endpoints in NASH; 45% mean liver fat reduction at 6mg.
- TERN-701 Phase 1 for CML and TERN-601 Phase 1 for obesity both on track to start H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023039867/0000950170-23-039867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023039867/tern-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer